Exploration of Phosphoproteins in Acinetobacter baumannii

Lisa Brémard1, Sébastien Massier1, Emmanuelle Dé1

  • 1University of Rouen Normandy, INSA Rouen Normandie, CNRS, Polymers, Biopolymers, Surfaces Laboratory UMR 6270, 76000 Rouen, France.

PubMed

Insights

This study optimized phosphopeptide enrichment in Acinetobacter baumannii, identifying 384 phosphorylation sites. These findings reveal new insights into antibiotic resistance and virulence mechanisms in this critical pathogen.

Area of Science:

  • Microbiology
  • Proteomics
  • Biochemistry

Background:

  • Acinetobacter baumannii is a multidrug-resistant pathogen causing hospital-acquired infections.
  • The World Health Organization designates it a critical priority pathogen, necessitating novel therapeutics.
  • Post-translational modifications (PTMs), like phosphorylation, regulate bacterial functions, including resistance and virulence.

Purpose of the Study:

  • To optimize phosphopeptide enrichment for Acinetobacter baumannii.
  • To characterize serine, threonine, and tyrosine phosphorylation in A. baumannii ATCC 17978.
  • To identify novel phosphosites and their functional implications.

Main Methods:

  • Optimization of three phosphopeptide enrichment parameters using titanium dioxide (TiO2) beads.
  • Evaluation of enrichment fractions, peptide quantity, and loading buffer type.
  • Proteomic analysis to identify phosphorylated peptides and proteins.

Main Results:

  • Identification of 384 unique phosphorylation sites on 241 proteins.
  • Discovery of 260 novel phosphosites in A. baumannii.
  • Characterization of phosphoproteins involved in antimicrobial resistance, biofilm formation, and pathogenicity.
  • Localization of 34 phosphosites to functional protein sites.

Conclusions:

  • The optimized protocol significantly enhances phosphopeptide identification in A. baumannii.
  • Phosphorylation plays a crucial regulatory role in A. baumannii physiology and virulence.
  • This study expands the known phosphoproteomic landscape, offering targets for therapeutic development.